XDH and chronic kidney disease: In a longitudinal cohort study of 2,724 subjects with cardiovascular risk factors (hypertension, diabetes, dyslipidemia, or chronic kidney disease), XO inhibitors’ (allopurinol and febuxostat) use was associated with a significantly lower risk of cardiovascular events over a median follow-up of 2.7 years.